There are currently 99 active clinical trials seeking participants for Endometrial Cancer research studies. The states with the highest number of trials for Autism participants are New York, Texas, California and Ohio.
Improving Care After Inherited Cancer Testing
NCT04763915
Recruiting
The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genetic test results for individuals with a documented pathogenic/likely pathogenic (P/LP) variant, and FC of family cancer history for individuals with a variant of uncertain significance (VUS) in an inherited cancer gene.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/09/2024
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: Inherited Cancer Syndrome, Prostate Cancer, Colorectal Cancer, Endometrial Cancer, Breast Cancer
Register for Updates
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
NCT05263492
Recruiting
Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer
Register for Updates
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
Recruiting
This Phase 1/2 study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 (INN: rezatapopt) alone (monotherapy) and in combination with pembrolizumab in participants with advanced solid tumors containing a TP53 Y220C mutation.
Gender:
All
Ages:
12 years and above
Trial Updated:
02/07/2024
Locations: City of Hope, Duarte, California +54 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
Register for Updates
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT05032040
Recruiting
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: UCSD Moores Cancer Center, La Jolla, California +11 locations
Conditions: Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Register for Updates
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT05819892
Recruiting
To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Cancer
Register for Updates
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
NCT06136884
Recruiting
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/16/2024
Locations: Oklahoma Univeristy, Oklahoma City, Oklahoma +1 locations
Conditions: Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer
Register for Updates
Choices About Genetic Testing And Learning Your Risk With Smart Technology
NCT06184867
Recruiting
The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among cancer survivors. The study objectives are to: Finalize the development and optimize usability of the CATALYST digital intervention (i.e., also known as relational assistant (RA)) Evaluate the feasibility and acceptability of a streamlined cancer genomic care delivery model in cancer survivors. Participants will be randomized to one of two study arms: the RA intervention v... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/03/2024
Locations: Rutgers University, New Brunswick, New Jersey
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, Pancreas Cancer, Colorectal Cancer, Endometrial Cancer, Prostate Cancer
Register for Updates
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
NCT04486352
Recruiting
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/22/2023
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +19 locations
Conditions: Endometrial Cancer
Register for Updates
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
NCT03746431
Recruiting
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, PK, and preliminary anti-tumour activity of [225Ac]-FPI-1434 (radioimmuno-therapeutic agent) in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547 (radioimmuno-imaging agent), and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of [225Ac]-FPI-1434 Injection in patients with solid tum... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/21/2023
Locations: City of Hope, Duarte, California +12 locations
Conditions: Advanced Solid Tumours, Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Adrenocortical Carcinoma, Uveal Melanoma
Register for Updates
Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
NCT03526432
Recruiting
This is a single arm, Phase II study using the combination of atezolizumab and bevicacizumab in women with advanced, recurrent or persistent endometrial cancer. Safety and futility of this drug combination will be assessed to see what effect this treatment has on this patient population.
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/04/2023
Locations: UAB Women and Infants Center, Birmingham, Alabama +2 locations
Conditions: Endometrial Cancer
Register for Updates
TH1902 in Patients With Advanced Solid Tumors
NCT04706962
Recruiting
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effective therapies exist. Part 2 (expansion): selected patient populations with recurrent advanced TNBC, HR+ breast cancer, epithelial ovarian cancer, endometrial cancer, cutaneous melanoma, thyroid cancer, SCLC, p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Karmanos Cancer Institute, Detroit, Michigan +5 locations
Conditions: Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
Register for Updates
Time Restricted Eating (TRE) Among Endometrial Cancer Patients
NCT04783467
Recruiting
The long-term goal of this study is to determine the efficacy of Time Restricted Eating (TRE) for improving metabolic health, preventing cardiometabolic comorbidities, and improving prognosis after endometrial cancer diagnosis. The primary objective of the protocol is to conduct a 16-week randomized dietary crossover study to evaluate the feasibility, fidelity and preliminary acceptability of TRE among endometrial cancer patients, and to provide proof of principle that TRE can improve metabolic... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Endometrial Cancer
Register for Updates